AstraZeneca Pharma faces Rs 1.88 lakh ROC penalty for delayed MD filing
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
AstraZeneca Pharma India has been penalised Rs 1.88 lakh by the Registrar of Companies, Bengaluru for delay in filing Form MR-2 related to the 2023 appointment of Dr Sanjeev Kumar Panchal as Managing Director. The Company blamed MCA portal technical glitches that wrongly flagged the DIN as inactive. Officers have each been fined Rs 50,000. Dr Panchal served as MD from January 2023 to June 2025.
Minor penalty with limited financial impact. A procedural compliance issue disclosed under SEBI rules, unlikely to affect operations or share price.